[Correlation study between the levels of serum MCP-1,SAA and cognitive function in patients with COPD-OSAHS]

Abstract

Objective:To study the correlation among the serum monocyte chemoattractant protein-1 (MCP-1),serum amyloid A(SAA) and the level of cognitive function in patients with chronic obstructive pulmonary disease and obstructive sleep apnea hypopnea syndrome overlap syndrome(OS).Method:Sixty patients with OS were in the experimental group, and 33 patients with COPD were in control group. The serum levels of MCP-1 and SAA were measured, and the correlation among MCP-1, SAA and cognitive function was observed by the Montreal scale.Result:①The serum levels of MCP-1 and SAA in OS group were (159.85±21.38)ng/L and (122.64±42.49)ng/L respectively,which in control group were (135.02±15.31)ng/L and (71.37±10.16)ng/L respectively.There were the was statistically significant difference between the two groups(P<0.05). ②Montreal scale score and its sub items in OS group were lower than the control group.The difference was statistically significant (P<0.05).③There was significant negative correlation between Montreal scale and the serum levels of MCP-1(r=-0.654,P<0.05) and SAA (r=-0.617,P<0.05) in OS group.Conclusion:Patients in the OS group had obvious cognitive impairment compared with the ones in control group, which suggested that OSAHS might be an independent risk factor for cognitive impairment. The cognitive function of OS patients was negatively related to MCP-1 and SAA, which suggested that MCP-1 and SAA played a role in the occurrence of cognitive impairment in OS patients.

Keywords: chronic obstructive pulmonary disease; cognitive function; montreal cognitive assessment; serum amyloid a protein; serum monocyte chemotactic protein-1; sleep apnea hypopnea syndrome,obstructive.